FibroGen (NASDAQ:FGEN) Announces Earnings Results

FibroGen (NASDAQ:FGEN) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports.

FibroGen Stock Performance

Shares of FGEN stock traded up $0.01 on Monday, reaching $0.45. 1,363,565 shares of the company were exchanged, compared to its average volume of 2,320,349. The company has a market cap of $44.84 million, a price-to-earnings ratio of -0.36 and a beta of 0.82. The business has a 50-day moving average price of $0.51 and a 200 day moving average price of $0.43. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on FGEN. StockNews.com started coverage on shares of FibroGen in a report on Friday. They issued a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of FibroGen in a research report on Thursday, February 20th.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.